Compare INM & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INM | SVRE |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Canada | Israel |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.8M |
| IPO Year | 2020 | N/A |
| Metric | INM | SVRE |
|---|---|---|
| Price | $0.70 | $4.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.3K | ★ 36.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,942,633.00 | N/A |
| Revenue This Year | N/A | $1,793.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $0.58 | $0.55 |
| 52 Week High | $7.98 | $5.69 |
| Indicator | INM | SVRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 59.09 |
| Support Level | $0.58 | $1.30 |
| Resistance Level | $0.94 | $4.92 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 38.91 | 54.52 |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.